Tech Company Financing Transactions
Solarea Bio Funding Round
Bold Capital Partners, S2G Ventures and GISEV Family Office participated in a $11.2 million Series A funding round for Solarea Bio. The financing round was announced on 10/20/2020.
Transaction Overview
Company Name
Announced On
10/20/2020
Transaction Type
Venture Equity
Amount
$11,200,000
Round
Series A
Investors
Bold Capital Partners (Lead Investor)
S2G Ventures (Lead Investor)
Proceeds Purpose
The company will use the proceeds from its Series A to advance its musculoskeletal product, SBD111, through a clinical proof of activity trial as well as continue the discovery and development of its ongoing pipeline of microbial-based products.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
100 Edwin H Land Blvd.
Cambridge, MA 02142
USA
Cambridge, MA 02142
USA
Phone
Undisclosed
Website
Email Address
Overview
The Solarea breakthrough came from the combined efforts of the company's co-founders who established a link between the discovery of an untapped source of microorganisms with probiotic potential in healthy foods, and their applications in inflammatory processes including the gut-musculoskeletal axis.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Gerardo Toledo
VP - General Counsel
Gregory Sieczkiewicz
VP - R & D
Eric Schott
Browse more venture capital transactions:
Prev: 10/20/2020: Canela Media venture capital transaction
Next: 10/21/2020: Verifiable venture capital transaction
Share this article
About Our VC Transactions Data
We do our best to record every notable VC transaction. VC investment data records on this site come from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs